The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients
with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung
disease (ILD). Patients who meet criteria for ILD-progression (defined below in
inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic
therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol,
including administration of multiple doses of hyperpolarized 129Xe. The subjects will have
this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at
3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate
anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat
studies will initiate based on time after enrollment.